Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin studies this year.

Sam Altman, the CEO of OpenAI, has announced a shift in his previously critical perspective on President Donald Trump. Newsweek has contacted OpenAI and the White House for comment via email.

Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT reports.

OpenAI CEO Sam Altman took the technology world by surprise on Thursday with the release of Operator, his company's first AI agent that can act

The latest spat began after Altman joined Trump, SoftBank CEO Masayoshi Son, and Oracle Chairman Larry Ellison in a White House ceremony on Tuesday to announce the launch of Stargate, a $500 billion venture to advance the United States’ artificial intelligence infrastructure.

"I genuinely respect your accomplishments and think you are the most inspiring entrepreneur of our time," Altman wrote in an X post to Musk.

With speculation online about OpenAI having reached the AGI stage of ChatGPT development, Sam Altman says that's not what's happening.

Tensions between technology leaders Elon Musk and OpenAI CEO Sam Altman were on full display this week after the Tesla CEO slammed the new artificial intelligence (AI) infrastructure project,

More orders are expected Tuesday amid fallout from his first moves, including his issuing pardons for more than a thousand rioters convicted in connection with the violent Jan. 6 attack on the U.S. Capitol and his effort to end birthright citizenship.

Their mutual friction goes back to the foundational ideals of OpenAI. But now both seem to have Trump’s favour: Elon Musk as DOGE boss and Sam Altman as a participant in America’s Stargate project.

OpenAI has recently released its first AI agent, Operator. But how is it different from the ChatGPT platform? Let's find out.